Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
2.
Semin Arthritis Rheum ; 46(6): 759-766, 2017 06.
Article in English | MEDLINE | ID: mdl-28214014

ABSTRACT

OBJECTIVES: Ischemic digital ulcers (DU) represent a major complication of systemic sclerosis (SSc). We investigated the impact of controlling the ulcerative disease on disability, pain, and quality of life in SSc patients receiving bosentan. METHODS: ECLIPSE (Study AC-052-517) is a 2-year prospective, multicenter, and observational study. Patients with SSc who experienced at least 1 DU in the previous year and received bosentan were included between October 2009 and March 2011. Disability scores [Cochin Hand Function Scale (CHFS) and Health Assessment Questionnaire Disability Index (HAQ-DI)], pain scores (visual analog scale), and quality-of-life scores (SF-36) were collected at inclusion and 1 year later (primary endpoint). A controlled ulcerative disease was defined by the absence of ongoing/new DU episode between inclusion and 1-year follow-up. RESULTS: Data were available at 1 year for 120 patients out of 190 included. During follow-up, 46 (38.3%) patients experienced a new DU episode. The number of DU per patient decreased from 1.4 ± 1.8 at inclusion to 0.6 ± 1.6 (p < 0.0001) at 1 year. Disability scores decreased from 1.0 ± 0.7 to 0.9 ± 0.7 (p = 0.04) for the HAQ-DI and from 29 ± 20 to 25 ± 20 (p = 0.005) for the CHFS; the pain score decreased from 4.3 ± 3.1 to 2.9 ± 2.8 (p < 0.0001). This improvement was attributed to patients with a controlled ulcerative disease (48.3%), who significantly improved HAQ-DI (p = 0.04), CHFS (p = 0.04), and pain score (p = 0.046). CONCLUSIONS: In patients with SSc, control of the ulcerative disease for 1 year was associated with significant attenuation of hand disability.


Subject(s)
Endothelin Receptor Antagonists/therapeutic use , Hand/physiopathology , Quality of Life , Scleroderma, Systemic/drug therapy , Skin Ulcer/drug therapy , Sulfonamides/therapeutic use , Adult , Aged , Bosentan , Disability Evaluation , Female , Humans , Male , Middle Aged , Prospective Studies , Scleroderma, Systemic/complications , Scleroderma, Systemic/diagnosis , Scleroderma, Systemic/physiopathology , Severity of Illness Index , Skin Ulcer/diagnosis , Skin Ulcer/etiology , Skin Ulcer/physiopathology , Treatment Outcome
4.
J Rheumatol ; 41(7): 1317-23, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24931950

ABSTRACT

OBJECTIVE: Ischemic digital ulcers (DU) are frequent and severe complications of systemic sclerosis (SSc). The purpose of our study was to assess the effect of DU on hand disability and pain in patients with SSc. METHODS: The Evaluation of the Impact of Recurrent Ischemic DU on Hand Disability in Patients with SSc (ECLIPSE) is a prospective, multicenter, noninterventional study with a 2-year followup. Patients with SSc who experienced at least 1 DU in the previous year and received bosentan therapy were included between October 2009 and March 2011. This cohort is described at the time of inclusion. RESULTS: There were 190 patients (132 females) from 53 centers. Mean age ± SD was 43 ± 15 years at SSc diagnosis and 53 ± 15 years at inclusion. In 105 patients (56.2%), DU were the first non-Raynaud symptoms of SSc. The mean time interval between the occurrence of Raynaud phenomenon and the first DU episode was 6.6 ± 9.1 years. The mean numbers of active DU and fingers affected per patient for both hands were 2.3 ± 1.8 and 2.2 ± 1.6, respectively. Presence of active DU at inclusion was significantly associated with pain and impaired hand function: Visual Analog Scale for pain (0 to 10) was 6.2 ± 2.6 versus 2.5 ± 2.4 (p < 0.0001) and Cochin Hand Function Scale for hand disability (0 to 90) was 38 ± 20 versus 25 ± 19 (p < 0.0001), respectively. CONCLUSION: DU represent a major sign of SSc, often affecting multiple fingers and both hands. They are significantly associated with pain and hand disability.


Subject(s)
Pain/etiology , Scleroderma, Systemic/complications , Skin Ulcer/etiology , Adult , Aged , Disability Evaluation , Female , Fingers , Humans , Male , Middle Aged , Pain/physiopathology , Prospective Studies , Scleroderma, Systemic/physiopathology , Skin Ulcer/physiopathology
5.
Semin Arthritis Rheum ; 43(5): 681-8, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24120178

ABSTRACT

OBJECTIVES: To describe the prevalence, characteristics, and outcome of cutaneous ischemia, and whether it can occur in systemic necrotizing vasculitides (SNVs), i.e., polyarteritis nodosa, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis. METHODS: We conducted a retrospective analysis of all patients with SNV who were included in the French Vasculitis Study Group cohort database between March 1963 and September 2007. We compared characteristics and outcomes for patients with and without cutaneous ischemia (digital necrosis and/or isolated necrotic cutaneous ulcers). RESULTS: Among the 1304 patients with a diagnosis of SNVs, 40 (3.1%) had digital necrosis and 25 (1.9%) had isolated necrotic cutaneous ulcers, with an equal distribution among SNVs. Presence of cutaneous ischemia was associated with past and/or current smoking [odds ratio (OR), 1.73; 95% confidence interval (95% CI), 1.02-2.95] and history of coronary artery disease (2.40; 1.01-6.00), as well as with other cutaneous manifestations (6.54; 3.21-8.67), gastrointestinal tract perforations (4.29; 1.41-13.07), and arthralgias (1.84; 1.10-3.07) during diagnosis. Ten patients with digital necrosis underwent extremity amputation, but no patient with isolated necrotic cutaneous ulcers (p = 0.007) underwent it. Smoking was the main risk factor of amputation (OR, 9.1; 1.7-48.9). At a mean follow-up of 10 years, cutaneous ischemia was identified as an independent predictor of vasculitis relapse (hazard ratio, 1.47; 95% CI, 1.05-2.05) and all-cause death (1.66; 1.01-2.74). CONCLUSIONS: Cutaneous ischemia is a rare manifestation of SNVs but is associated with an increased risk of relapse and mortality. Tobacco use is associated with amputation, which emphasizes the importance of managing conventional cardiovascular risk factors in SNV patients.


Subject(s)
Gangrene/pathology , Skin/blood supply , Systemic Vasculitis/pathology , Adult , Aged , Female , Gangrene/epidemiology , Humans , Male , Middle Aged , Prevalence , Prognosis , Retrospective Studies , Skin/pathology , Systemic Vasculitis/epidemiology
6.
Brain Behav Immun ; 35: 51-7, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23917070

ABSTRACT

BACKGROUND: Mastocytosisis a rare disease associated with chronic symptoms related to mast cell mediator release. Patients with mastocytosis display high level of negative emotionality such as depression and stress sensibility. Brain mast cells are mainly localized in the diencephalon, which is linked to emotion regulatory systems. Negative emotionality has been shown to be associated with telomere shortening. Taken together these observations led us to hypothesize that mast cells activity could be involved in both negative emotionality and telomere shortening in mastocytosis. OBJECTIVE: To demonstrate a possible relationship between negative emotionality in mastocytosis and leukocytes telomere length. METHODS: Leukocyte telomere length and telomerase activity were measured among mastocytosis patients and were correlated with perceived stress and depression assessed by the Beck Depression Inventory revised and the Perceived Stress Scale. RESULTS: Mild-severe depression scores were frequent (78.9%) as well as high perceived stress (42.11%). Telomere length was correlated to perceived stress (r=0.77; p=0.0001) but not to depression in our population. Patients displaying Wild-type KIT significantly presented higher perceived stress levels. Patients with the D816VC KIT mutation who had high perceived stress scores displayed significantly shorter telomere but not if they had high depression scores. CONCLUSION: These findings suggest that high perceived stress in mastocytosis could accelerate the rate of leukocytes telomere shortening. Since mastocytosis is, by definition, a mast cell mediated disease; these cells could be involved in this phenomenon. Mechanistic causal relationships between these parameters need to be investigated.


Subject(s)
Depression/genetics , Mastocytosis/genetics , Mastocytosis/psychology , Stress, Psychological/genetics , Telomere Shortening , Adult , Aged , Female , Humans , Leukocytes, Mononuclear/metabolism , Male , Middle Aged , Young Adult
8.
PLoS One ; 8(11): e79414, 2013.
Article in English | MEDLINE | ID: mdl-24223945

ABSTRACT

BACKGROUND: Neurotrophins play a central role in the development and maintenance of the nervous system. However, neurotrophins can also modulate B and T cell proliferation and activation, especially via autocrine loops. We hypothesized that both serum and lymphocytic neurotrophin levels may be deregulated in systemic Lupus erythematosus (SLE) and may reflect clinical symptoms of the disease. METHODS: Neurotrophins in the serum (ELISA tests) and lymphocytes (flow cytometry) were measured in 26 SLE patients and 26 control subjects. Th1 (interferon-γ) and Th2 (IL-10) profiles and serum concentration of BAFF were assessed by ELISA in the SLE and control subjects. FINDINGS: We have demonstrated that both NGF and BDNF serum levels are higher in SLE patients than healthy controls (p=0.003 and p<0.001), independently of Th1 or Th2 profiles. Enhanced serum NT-3 levels (p=0.003) were only found in severe lupus flares (i.e. SLEDAI ≥ 10) and significantly correlated with complement activation (decreased CH 50, Γ=-0.28, p=0.03). Furthermore, there was a negative correlation between serum NGF levels and the number of circulating T regulatory cells (Γ=0.48, p=0.01). In circulating B cells, production of both NGF and BDNF was greater in SLE patients than in healthy controls. In particular, the number of NGF-secreting B cells correlated with decreased complement levels (p=0.05). One month after SLE flare treatment, BDNF levels decreased; in contrast, NGF and NT-3 levels remained unchanged. CONCLUSION: This study demonstrates that serum and B cell levels of both NGF and BDNF are increased in SLE, suggesting that the neurotrophin production pathway is deregulated in this disease. These results must be confirmed in a larger study with naive SLE patients, in order to avoid the potential confounding influence of prior immune-modulating treatments on neurotrophin levels.


Subject(s)
Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/immunology , Lymphocytes/metabolism , Nerve Growth Factors/blood , Adult , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Case-Control Studies , Female , Gene Expression Regulation , Humans , Lupus Erythematosus, Systemic/therapy , Lymphocytes/immunology , Male , Nerve Growth Factors/metabolism , Quality of Life
10.
Oncol Rep ; 29(3): 1196-200, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23242333

ABSTRACT

Photodynamic therapy (PDT) is now a well-established treatment modality for cutaneous carcinomas and is based on the administration of a light-activated drug followed by illumination of the pathological area. The treatment of metastatic melanoma remains a therapeutic challenge. To define the possible role of melanin in relative phototoxicity of 5-aminolevulinic acid (5-ALA), a photosensitizer used in PDT in vivo, we studied cell death in two variants (with or without melanin, B16F10 and B16G4F cells, respectively) of a melanoma cell line. Concentrations of 5-Ala up to 10 mM induced similar cytostatic effects in the B16G4F and B16F10 cells. PDT and high 5-ALA concentrations induced photocytotoxicity in both melanoma cell lines (at 10 mM for B16F10 cells and at 5 mM for B16G4F cells). Cell death corresponded to p53-dependent apoptotic signaling in pigmented B16F10 cells, whereas an autophagic response leading to a caspase-independent death was detected in non-pigmented B16G4F cells. Therefore, the PDT-induced cell death pathway appeared to correlate with melanin synthesis capacity in melanoma cells. To reduce the cytotoxicity of 5-ALA without irradiation, a low drug concentration could be used. Consequently, in combination with current therapeutics, a moderate concentration of 5-ALA and PDT may constitute a supplementary promising approach to eliminate metastatic melanoma.


Subject(s)
Aminolevulinic Acid/pharmacology , Apoptosis/drug effects , Autophagy/drug effects , Melanins/metabolism , Photosensitizing Agents/pharmacology , Animals , Apoptosis Regulatory Proteins/metabolism , Beclin-1 , Caspases/metabolism , Cathepsin B/metabolism , Cell Line, Tumor , Cell Survival/drug effects , Cell Survival/radiation effects , Melanoma, Experimental , Mice , Microtubule-Associated Proteins/metabolism , Photochemotherapy , Signal Transduction , Tumor Suppressor Protein p53/metabolism , Tumor Suppressor Proteins/metabolism
11.
J Invest Dermatol ; 132(8): 1998-2004, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22418872

ABSTRACT

A major increase in the incidence of BP has been recently reported in the United Kingdom. In addition, there are some controversies about the over-mortality of BP patients. The primary objective was to reevaluate the incidence of BP in France as compared with that we estimated 15 years ago. The secondary objective was to assess mortality of BP patients. BP incidence was retrospectively estimated from all BP cases diagnosed between January 2000 and December 2005 in three French regions with a total population of 3.858 million inhabitants. BP mortality was assessed from a prospective cohort accrued during the same time period. A total of 502 incident BP patients (mean age: 82.6±8.8 years) were identified. Overall estimated incidence was 21.7 cases per million persons per year (95%CI:19.8-23.7 cases per million persons per year), which is about 3-fold higher than the incidence that we estimated 15 years ago. In the population aged 70 years or above, BP incidence was 162 cases per million per year (95%CI:147-177 cases per million per year). The overall 1-year survival rate was 62% (95% CI: 56-67%). The risk of death for BP patients was more than six times greater than that for the general population (SMR:6.60; 95%CI:5.47-7.90). The incidence of BP in France has increased 3-fold in the last 15 years. BP is associated with high mortality.


Subject(s)
Pemphigoid, Bullous/epidemiology , Pemphigoid, Bullous/mortality , Age Factors , Aged , Aged, 80 and over , Cohort Studies , Female , France , Humans , Incidence , Male , Middle Aged , Models, Statistical , Mortality , Prospective Studies , Treatment Outcome
12.
Photochem Photobiol ; 88(4): 1023-6, 2012.
Article in English | MEDLINE | ID: mdl-22332671

ABSTRACT

Many studies have been conducted showing that aminolevulinic acid (ALA)-photodynamic therapy (PDT) can be an alternative treatment for recalcitrant warts. Recently, we performed a study evaluating methyl-aminolevulinic acid (MAL)-PDT for the treatment of hand warts in a population of renal transplant patients. Two symmetrical targets were selected on each hand and randomly assigned to chemical keratolytic treatment followed by three cycles of ALA-PDT (75 J cm(-2) red light). Patients were evaluated after 3 months and a second run of PDT was performed if the total area and number of warts decreased less than 50%, with evaluation every 3 months for 1 year. Twenty patients were included and 16 were evaluable (9 M, 7 F). After 6 months the reduction of warts' area was 48.4% on the treated side versus 18.4% in the control area (P = 0.021). The decrease in the total number of warts was 41%versus 19.4% (P = NS). The global tolerance of the treatment was good with acceptable pain during irradiation. These results suggest that ALA-PDT is a safe and efficient treatment for transplanted patient warts. The improvement between treated and control zone is 20% due to the decrease in untreated warts' area and number.


Subject(s)
Aminolevulinic Acid/analogs & derivatives , Kidney Transplantation/immunology , Photochemotherapy , Photosensitizing Agents/administration & dosage , Warts/drug therapy , Adult , Aminolevulinic Acid/administration & dosage , Female , Hand/virology , Humans , Immunocompromised Host , Light , Male , Middle Aged , Prospective Studies , Treatment Outcome , Warts/immunology , Warts/virology
13.
J Invest Dermatol ; 131(3): 637-43, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20944650

ABSTRACT

A rise in the incidence of bullous pemphigoid (BP) was documented recently in Europe, and the main risk factors for BP remain unknown. We conducted a multicenter case-control study to evaluate risk factors for BP. We identified 201 incident BP cases and 345 controls individually matched for age, gender, center, and place of residence (home, nursing home, or extended-care facility). We used univariate and multivariate logistic regression analyses to compare drugs used for over 3 months, comorbidities, and physical and cognitive impairments between cases and controls. Mean age of BP patients was 84.2 (±8.7) years. Factors independently associated with BP by multivariate analysis were major cognitive impairment (odds ratio (OR), 2.19; 95% confidence interval (95% CI), 1.24-3.87), bedridden condition (OR, 2.19; 95% CI, 1.23-3.89), Parkinson's disease (OR, 2.16; 95% CI, 1.09-4.27), unipolar or bipolar disorder (OR, 5.25; 95% CI, 1.21-22.86), and chronic use of spironolactone (OR, 2.30; 95% CI, 1.20-4.46) or phenothiazines with aliphatic side chains (OR, 3.70; 95% CI, 1.21-11.34). Chronic analgesic use was associated with a lower risk of BP (OR, 0.49; 95% CI, 0.30-0.81). Thus, risk factors for BP include neurological disorders, particularly dementia and Parkinson's disease, psychiatric disorders (unipolar and bipolar disorders), bedridden condition, and chronic use of several drugs.


Subject(s)
Antipsychotic Agents/adverse effects , Bed Rest/adverse effects , Nervous System Diseases/complications , Pemphigoid, Bullous/epidemiology , Aged , Aged, 80 and over , Bipolar Disorder/complications , Case-Control Studies , Cognition Disorders/complications , Female , France/epidemiology , Humans , Male , Multivariate Analysis , Parkinson Disease/complications , Phenothiazines/adverse effects , Prospective Studies , Risk Factors , Spironolactone/adverse effects
14.
PLoS One ; 5(11): e13918, 2010 Nov 09.
Article in English | MEDLINE | ID: mdl-21085492

ABSTRACT

BACKGROUND: Neurotrophins (NTs) are able to activate lymphocytes and fibroblasts; they can modulate angiogenesis and sympathic vascular function. Thus, they can be implicated in the three pathogenic processes of systemic sclerosis (SSc). The aims of this study are to determine blood levels of Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) in SSc and to correlate them with clinical and biological data. METHODS: Serum samples were obtained from 55 SSc patients and 32 control subjects to measure NTs levels by ELISA and to determine their relationships with SSc profiles. FINDINGS: Serum NGF levels were higher in SSc patients (288.26 ± 170.34 pg/mL) than in control subjects (170.34 ± 50.8 pg/mL, p<0.001) and correlated with gammaglobulins levels and the presence of both anti-cardiolipin and anti-Scl-70 antibodies (p<0.05). In contrast, BDNF levels were lower in SSc patients than in controls (1121.9 ± 158.1 vs 1372.9 ± 190.9 pg/mL, p<0.0001), especially in pulmonary arterial hypertension and diffuse SSc as compared to limited forms (all p<0.05). NT-3 levels were similar in SSc and in the control group (2657.2 ± 2296 vs 2959.3 ± 2555 pg/mL, NS). BDNF levels correlated negatively with increased NGF levels in the SSc group (and not in controls). CONCLUSION: Low BDNF serum levels were not previously documented in SSc, particularly in the diffuse SSc subset and in patients with pulmonary hypertension or anti-Scl-70 antibodies. The negative correlation between NGF and BDNF levels observed in SSc and not in healthy controls could be implicated in sympathic vascular dysfunction in SSc.


Subject(s)
Brain-Derived Neurotrophic Factor/blood , Nerve Growth Factor/blood , Neurotrophin 3/blood , Scleroderma, Systemic/blood , Adult , Aged , Antibodies, Anticardiolipin/blood , Autoantibodies/blood , B-Lymphocytes/metabolism , DNA Topoisomerases, Type I , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Nuclear Proteins/immunology , Scleroderma, Systemic/immunology , T-Lymphocytes/metabolism
15.
Anticancer Res ; 30(1): 143-7, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20150629

ABSTRACT

UNLABELLED: The large number of studies devoted to the effect of ultraviolet light on biological systems, contrasts with the lack of experimental data concerning the direct effects of visible light. It has been shown that blue light inhibited the growth of B16F10 melanoma cell lines and reduced the percentage of S phase cells. Yet these effects are poorly understood. MATERIALS AND METHODS: Two cell lines and irradiation with blue light were used. Cell mortality and a possible mechanism of action were investigated. RESULTS: Exposure of B16F10 melanoma and bovine endothelial cells to blue light (wavelength 450 nm, 10 J/cm(2) from a Waldman lamp) induced a rapid and large reduction in viability followed by the death of virtually all the irradiated cells within 24 h. These results led us to expose a patient with haemorrhagic cutaneous melanoma metastasis to blue light. Irradiation led to an immediate arrest of haemorrhage, an inhibition of tumour growth and extensive tumour necrosis 24h after irradiation. CONCLUSION: Exposure to blue light may offer new approaches to the treatment of superficial skin carcinomas in humans.


Subject(s)
Endothelial Cells/radiation effects , Melanoma, Experimental/therapy , Phototherapy/methods , Animals , Cattle , Cell Survival/radiation effects , Endothelial Cells/cytology , Endothelial Cells/metabolism , Light , Lipid Peroxidation/radiation effects , Melanoma, Experimental/metabolism , Melanoma, Experimental/pathology , Mice
16.
J Invest Dermatol ; 129(7): 1681-7, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19177141

ABSTRACT

Superpotent topical corticosteroids (CS) have been demonstrated to improve bullous pemphigoid (BP) patients' survival. We assessed whether a mild regimen using lower doses of topical CS and a shorter duration could improve the outcome of BP patients even more. Three-hundred and twelve BP patients were included in a multicenter randomized controlled trial and stratified depending on the extent of BP as moderate (n=134) or extensive (n=178). Patients were randomly assigned to the standard regimen (clobetasol propionate cream, 40 g per day initially, with CS tapering over 12 months) or the mild regimen (10-30 g per day), with CS tapering over 4 months. A noninferior rate of BP control was obtained with the mild regimen 156/159 (98%) as compared with the standard regimen 150/150 (100%; P=0.005). Event-free survival, that is, the combined outcome of deaths and life-threatening adverse events did not differ between the two treatment groups (P=0.77). However, upon adjusting through the Cox model for age and Karnofsky score, a strong beneficial effect of the mild regimen was observed in patients with moderate BP, with an almost twofold decrease in the risk of death or life-threatening adverse events relative to the standard regimen (hazard ratio=0.54; 95% confidence interval, 0.30-0.97; P=0.039). This mild regimen allows a 70% reduction of the cumulative doses of CS and improves BP patients' outcome.


Subject(s)
Clobetasol/administration & dosage , Glucocorticoids/administration & dosage , Pemphigoid, Bullous/drug therapy , Administration, Topical , Adrenal Glands/drug effects , Aged , Aged, 80 and over , Clobetasol/adverse effects , Disease-Free Survival , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Glucocorticoids/adverse effects , Humans , Hypothalamo-Hypophyseal System/drug effects , Male , Proportional Hazards Models , Recurrence , Treatment Outcome
19.
Dermatology ; 215(1): 28-35, 2007.
Article in English | MEDLINE | ID: mdl-17587836

ABSTRACT

OBJECTIVE: To describe a series of hospitalized patients with eczema craquelé (EC) and the possible correlations between clinical features of EC and cancer in an open prospective observational study. PATIENTS AND INTERVENTIONS: The study population comprised 68 consecutive patients included between January 1, 1999 and December 31, 2000 who were followed up through December 2004. All patients who had localized or generalized EC were included. Patients underwent complete clinical examinations, routine laboratory tests, chest x-rays, abdominal ultrasound, and cutaneous biopsies performed on EC. MAIN OUTCOME MEASURES AND RESULTS: Rates of EC associated with cancer, clinical features of eczema, rate of recalcitrant eczema, relationship to other clinical prognostic factors, and paraneoplastic evolution were evaluated. Cancer was diagnosed in 32 patients (47%). We observed a significant difference in the presenting clinical signs of EC between patients with malignant tumors and patients without cancer. In patients with malignancies, EC was widespread on the trunk and we noted deep red and inflammatory fissures. In all cases, EC led to the discovery of malignancy or recurrence of cancer. CONCLUSION: Widespread EC, topical corticosteroid resistance, and deep red and inflammatory fissures were significantly correlated with neoplasia.


Subject(s)
Eczema/diagnosis , Eczema/epidemiology , Neoplasms/epidemiology , Neoplasms/pathology , Paraneoplastic Syndromes/diagnosis , Adult , Age Distribution , Aged , Aged, 80 and over , Cohort Studies , Comorbidity , Follow-Up Studies , Humans , Incidence , Middle Aged , Paraneoplastic Syndromes/epidemiology , Predictive Value of Tests , Prospective Studies , Prurigo/diagnosis , Prurigo/epidemiology , Severity of Illness Index , Sex Distribution , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...